CV6 THERAPEUTICS NI LTD has a total of 24 patent applications. It decreased the IP activity by 84.0%. Its first patent ever was published in 2016. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets organic fine chemistry and pharmaceuticals are DDSA PHARMACEUTICALS LTD, KINNATE BIOPHARMA INC and ARGONAUT THERAPEUTICS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | Australia | 1 | |
#4 | Brazil | 1 | |
#5 | Canada | 1 | |
#6 | EPO (European Patent Office) | 1 | |
#7 | Hong Kong | 1 | |
#8 | Israel | 1 | |
#9 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals |
# | Name | Total Patents |
---|---|---|
#1 | Spyvee Mark | 20 |
#2 | Shirude Pravin S | 8 |
#3 | Ladner Robert D | 5 |
#4 | Ladner Robert | 2 |
#5 | Pravin S Shirude | 2 |
#6 | Lewis Michael | 2 |
#7 | Mark Spyvee | 1 |
Publication | Filing date | Title |
---|---|---|
US2019276410A1 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | |
US2020039966A1 | Uracil containing compounds | |
WO2018098206A1 | Hydantoin containing deoxyuridine triphosphatase inhibitors | |
WO2018098207A1 | Hydantoin containing deoxyuridine triphosphatase inhibitors | |
WO2018098209A1 | Amino sulfonyl compounds | |
US2019270756A1 | 6-membered uracil isosteres | |
AU2016290987A1 | Hydantoin containing deoxyuridine triphosphatase inhibitors | |
US2018201586A1 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |